Open Access

Isolation and identification of Candida species in patients with orogastric cancer: susceptibility to antifungal drugs, attributes of virulence in vitro and immune response phenotype

  • Lourimar Viana Nascimento F. de Sousa1, 6Email author,
  • Vera Lúcia Santos2,
  • Andrea de Souza Monteiro3,
  • Marcus Vinicíus Dias-Souza2,
  • Sirlei Garcia Marques4,
  • Elaine Speziali de Faria5,
  • Elaine Alves de Oliveira Assunção6,
  • Simone Gonçalves dos Santos7,
  • Juan Moises Zonis8,
  • Daniel Gomes de Alvarenga9,
  • Rodrigo Assunção de Holanda1,
  • Jaqueline Gontijo de Sousa10,
  • Kênia Valéria dos Santos11 and
  • Maria Aparecida de Resende Stoianoff1
BMC Infectious DiseasesBMC series – open, inclusive and trusted201616:86

https://doi.org/10.1186/s12879-016-1431-4

Received: 12 May 2015

Accepted: 12 February 2016

Published: 23 February 2016

Abstract

Background

Because of the inherent immunosuppression of cancer patients opportunistic infections by Candida spp, occur frequently. This study aimed to identify Candida species in the oral mucosa of 59 patients with orogastric cancer (OGC) and to analyze the immunological phenotype of these patients.

Methods

The yeasts were identified by MALDI-TOF mass spectrometry (MS). For all isolates, we performed phospholipases and proteinases assays, in vitro adherence to buccal epithelial cells (BEC), minimum inhibitory concentration of antifungal drugs and determined the cytokine profile by Cytometric Bead Array flow citometry assay.

Results

C. albicans was the most prevalent species in OGC patients (51.6 %) and control group (66.7 %). Candida spp. strains isolated from OGC patients exhibited better adherence to BEC (p = 0.05) than did the control group. Phospholipases production by Candida strains from OGC patients was lower (51.6 %) than in the control group (61.9 %). Proteinases were detected in 41.9 % and 4.8 % of the yeasts from OGC patients and control group, respectively. Significant differences were found in the serum of OGC patients compared to the control group for IL-2, IL-10, TNF-α, IFN-γ and IL-17.

Conclusions

The results of this work suggest increased virulence of yeasts isolated from OGC patients and, that this may interfere with the immune phenotype.

Keywords

Candida spp Orogastric cancer Virulence Antifungal Immune phenotype

Background

Malignant neoplasms or cancer is defined as a chronic degenerative disease of rapid and abnormal growth of defective cells, which may spread through the body (metastasis) and increase the rate of mortality [1]. The process of carcinogenesis and oncogenesis comprises early changes in DNA to tumor formation, which may cause slow and progressive destruction of the host organism [2].

Cancer patients with metastasis have a high probability of mucocutaneous and bloodstream infections by fungi, including Candida species. Candidiasis is a fungal infection of extensive spectrum, which affects mainly immunocompromised patients. Candida species of medical interest, such as Candida albicans to non-albicans, C. glabrata, C. tropicalis, C. krusei and C. parapsilosis, can be found commensally in the microbiota of human cavities (such as rectal, oral, vaginal, urethral, nasal, and aural) and on skin, although their presence in the microbiota of healthy people remains unexplained. However, nutritional factors, interactions with the microbiota, and the presence of salivary antibodies have been suggested as possible influencing factors in the incidence of these yeasts, which are usually controlled by local factors, such as competition with bacterial cells of the resident microbiota [36].

Candida albicans is a dimorphic fungus that is part of the commensal microbiota of the oral cavity. When the host immune defenses are impaired or when the normal microbiota is disturbed, C. albicans triggers recurrent infections of the oral mucosa and tongue [3]. The yeast’s colonization and its ability to be an opportunistic pathogen make candidiasis common worldwide [3]. For cancer patients, in addition to the intrinsic factors related to treatment such as placement of central venous catheters and receipt of parenteral nutrition, there are additional risk factors for candidemia. In these individuals, there may exist chemotherapy-induced neutropenia and/or mucositis and radiation-induced tissue injury, which facilitate fungemia by Candida spp. [7, 8].

The pathogenicity of Candida spp. is related to a combination of factors contributing to their virulence, such as their ability to grow at 37 °C, their phenotypic variability (switching), their transition from budding-to-hyphae or pseudo-hyphae and biofilm formation. This pathogenicity is also related to the presence of homologous molecules, such as the human integrin CR3 receptor, which facilitates adherence to epithelial cells, and the ability to produce hydrolytic enzymes, such as phospholipases, aspartyl proteinases (Sap), and lipases [9, 10]. The adherence to the mucosal surface of the host probably occurs by the interaction between the microorganisms’adhesins and receptors on epithelial cells [11]. Secretion of phospholipases is considered a key attribute for the invasion of host mucosal epithelium, by disrupting the phospholipid bilayer, which is amajor component of all cell membranes [9].

Oropharyngeal candidiasis is the most common fungal infection that affects cancer patients. Particularly, patients in radiotherapy for head and neck cancer are more susceptible to colonization by Candida. It was described in murine models that mucocutaneous infections are usually associated with deficient cellular immune responses, and systemic infections are more related to innate immunity, characterized by impairments of neutrophil recruitment and activity [12, 13].

The guidelines of the American Society of Infectious Diseases recommends treatment with caspofungin and fluconazole for patients who had not been previously exposed to azoles or amphotericin B. The combined therapy of amphotericin B with fluconazole is recommended for the initial treatment of chronic candidemia, and 5-fluorocytosine combined with either of these drugs might be recommended [14]. The most relevant antifungal commercially available has similar pharmacodynamics, the fungal membrane sterols being the main targets [15].

There are different inflammatory responses in the tumor microenvironment, this contains the innate immune response cells, also found cells of the adaptive immune response, and cancer cells surrounding by stroma [16]. In this microenvironment, there are different interactions through cytokines, chemokines, and even interactions through direct contact, by interaction of cell receptors to activate or induce autocrine and paracrine pathways, in order to control the shape and tumor expansion. However, the expression of several mediators and modulation of immune response as well as the amount and state of activation of different types of cells in the tumor microenvironment that dictate whether the local inflammation will promote tumor growth or whether an immune response suppression cancer cells will follow [17, 18]. Patients with cancer present clinical cytokine patterns that suggest that simultaneous immunostimulation and immunosuppression occur in patients with cancer, with increased concentrations of the cytokines like TNFα, interleukin 6, interleukin 8, interleukin 10, and interleukin 18 [19]. Nevertheless, it was suggested that one specific cytokine pattern may have a prognostic effect, since high interleukin 6 or interleukin 10 serum concentrations are associated with negative prognoses in independent types of cancer [16].

The immune mechanisms of defense against fungal infections are numerous, and range from protective mechanisms that were present early in evolution (innate immunity) to sophisticated adaptive mechanisms that are induced specifically during infection and disease (adaptive immunity). The first-line innate mechanism is the presence of physical barriers in the form of skin and mucous membranes, which is complemented by cell membranes, cellular receptors and humoral factors. There has been a debate about the relative contribution of humoral and cellular immunity to host defense against fungal infections. Candida albicans, part of the normal microbial flora associated with mucous surfaces, can be present as congenital candidiasis or as acquired defects of cell-mediated immunity. Resistance to this yeast is associated with Th1, whereas Th2 immunity is associated with susceptibility to systemic infection [20].

Therefore, this study aimed to identify Candida species in the oral mucosa of patients with orogastric cancer and to analyze the immunological phenotype of these patients. Yeast strains were identified by standard taxonomic keys and Matrix Assisted Laser Desorption Ionization – Time Of Flight – Mass Spectrometry (MALDI-TOF). Phenotypic methods were employed for identifying virulence factors, and antifungal susceptibility testing was performed through broth microdilution. Furthermore, Cytometric Bead Array (CBA) flow citometry was used for the simultaneous detection and quantification of IL-2, IL-4, IL-6, IL-10, IL17, TNF-α and IFN-γ.

Methods

Patient selection and biological samples

The consent of the patients and the control group was made in writing, through the TIC (Term of informed consent) after this study is approved by the Research Ethics Committee of the University of Vale do Rio Doce (COEP PQ25 / 10-10). Fifty nine patients with orogastric cancer were selected. Cancer diagnosis was confirmed by histopathology assays, and thirty-four healthy individuals were selected for the control group. The control group comprised health professionals, dentists, and teachers from Univale University. These individuals were invited because this group should be made of people who did not show any alterations in the oral cavity, especially regarding the presence of carcinomas. These selected patients were free of any type of disease. The group of individuals with cancer had not started chemotherapy by the time of the commencement of the study. However, these individuals had positive diagnosis for cancer, confirmed by histopathological examination. Both groups were evaluated for the presence of Candida spp. The collection of the samples was performed by specialist physicians of Governador Valadares city (MG). Inclusion criteria for patients comprised a previous diagnosis of advanced cancer and not being subjected to chemotherapy or radiotherapy. Clinical specimens for microbiological analysis were collected using sterile swabs and placed in tubes containing Sabouraud dextrose broth (Difco®) with chloramphenicol (0.1 mg/mL), and these specimens were sent to the laboratory and incubated at 28 °C for 72 h for subsequent microbiological testing. Direct examination was not performed for the presence of pseudohyphae or fungal cells.

Isolation and identification of strains

The tubes containing yeasts were incubated without shaking in an incubator at 37 °C, disposed in galleries. Yeast strains were isolated after inoculation of positive samples in Sabouraud dextrose agar (SDA, Difco) Candida. The yeast isolates were inoculated in ChromagarCandida (Difco Laboratories, Detroit, MI) to obtain pure cultures and for morphological identification according to standard taxonomic keys [21, 22]. The tests used in the differentiation of Candida species were: (1) presence of growth at 42 and 45 °C [23], characteristic observed only for the C. albicans, (2) presence of growth on the hypertonic Sabouraud broth (NaCl 6.5 %) [24], characteristic observed only for the C. albicans; (3) Also, slide cultures were prepared to visualize the difference in the production of chlamydospores.

Slide culture and microscopy

A fragment of cornmeal agar prepared with Tween 80 was placed on a sterile glass slide. The yeast cells were inoculated by making the three central grooves in the agar fragment. The inoculum was covered with a sterile cover slip and incubated in sterile petri dish with a piece of cotton soaked in sterile water at 28 °C for approximately seven days. Yeast growth was analyzed after five days of incubation to study the formation of pseudohyphae, hyphae and chlamydospores to make the morphological identification.

Identification of yeasts by MALDI-TOF MS

The confirmation of Candida species by Matrix-Assisted Laser Desorption Ionization – Time-of-Flight Mass Spectrometry (MALDI-TOF MS) was performed using the VITEK–MS system (bioMérieux, Marcy-l’Etoile, France). Yeast cells were grown on SB agar medium plates for 24 h, at 37 °C. A loopful of yeast cells was directly transferred from the culture medium onto each position of the disposable target slides (bioMérieux, France), which were inoculated with a small amount of a single yeast colony to provide a thin layer of organism using a disposable plastic loop. Afterwards, 1 μL of 70 % formic acid was added to each sample on the target slide and allowed to air dry it before adding 1 μL of α-cyano-4-hydroxycinnamic acid matrix solution. Finally, the mass spectra acquired for each isolated yeast were compared to the known mass spectra contained in the database and given a confidence score according to how closely the acquired spectra matched those contained in the database. The resulting slides were then analyzed in the VITEK® MS instrument, using the automatic database analysis of the obtained mass spectra within MYLA® software (bioMérieux, France) to provide isolate identification.

Virulence factors

Hydrolytic enzymes

Sixty-two isolates of Candida spp. isolated from the oral cavity of patients with orogastric cancer and 21 isolates from the oral mucosa of individuals in the control group were selected for this assay. The methods we used to determine proteinases activity were recommended by Cassone et al. [25] and De Bernardis et al. [26]. Proteinases secretion was evaluated on solid medium containing 11.7 g of Yeast Carbon Base (Difco Laboratories,Detroit, MI, USA), 1.0 g of yeast extract, and 2.0 g of bovine serum albumin (BSA, Merck Sharp & Dohme, Kenilworth, NJ, USA)/100 mL of water. The pH was adjusted to 5.0, medium was sterilized by filtration and added to an agar solution sterilized by autoclaving (agar 18 g in 900 ml of distilled water). The inoculum consisted of a suspension of 106 cells/mL deposited on the agar. The plates were incubated for seven days at 28 °C and proteolysis of BSA was visualized as a clear halo after staining with amido black staining (1 g black starch, 199 mL glacial acetic acid, 100 mL distilled water). Proteinases activity was classified as negative if there were no visible clarification, 1+ when proteolysis surrounding the colony ranged from 1 to 2 mm, and 2+ when discoloration of agar exceeded 3-5 mm around the colony. The phospholipases production was verified using the egg yolk agar plate method according [27]. The Petri dishes were incubated at 37 °C, and the diameters of the colonies with the zones of precipitation were measured after 7 days of incubation. The zone of phospholipases (PZ) was calculated as the colony diameter divided by the diameter of the colony plus the precipitation zone. The production of protease was demonstrated by clear halos around the colonies on agar plates containing BSA. The PZ index was determined in the same way as for phospholipases. Each isolate was tested in duplicate.

Adhesion of Candida strains to BEC

For adhesion studies of yeasts in buccal epithelial cells, we used 26 isolates (C. albicans, C. tropicalis, C. glabrata and C. krusei) from cancer patients and 10 yeasts from patients in the control group (C. albicans, C. parapsilosis and C. glabrata). The yeast cells were pre-incubated in SDA plates and incubated at 37 °C for 24 h before the test to obtain the inoculum. The assay was performed as described by Machado et al [28]. Next, 3 colonies were transferred to 40 mL of Sabouraud broth (Difco). After incubation at 37 °C for additional 24 h, the yeasts were Gram stained in order to verify the purity of the suspension. Next, the cells were centrifuged (3000 g; 15’) and washed 3 times in 15 mL of saline phosphate buffer (PBS; pH 7.4). A suspension containing 107 cells/mL was obtained in a Neubauer chamber (Laboroptik, Friedrichsdorf, Hesse, Germany) using the Trypan blue exclusion method.

The assay was performed as described by Kimura and Pearsall [29] Human buccal cells (HBECs) were harvested from a healthy young adult non-carrier of Candida yeasts in the oral cavity with two sterile swabs and added to 10 mL PBS. The BEC suspension was washed four times and centrifuged to remove adherent microorganisms (3000 g, 10 min). The suspension of the yeasts was then diluted to a concentration of 105 cells/mL, counted with a Neubauer chamber and used immediately. For the test, 0.5 ml of the BEC suspension (1 x 105 cell/ml) and 0.5 ml of the yeast suspensions (1 x 107 cell/ml) were mixed gently and incubated at 37 °C for 1 hourunder shaking (40 rpm).

The cells were then harvested on polycarbonate membranes with an 8-μm pore diameter (Sartorius-Stedim, Biotech) and washed with PBS to remove non-adhering yeast. The filter was removed with the aid of forceps and pressed against a glass slide. After 10 s, the filter was gently removed, leaving the BEC adhered to the glass slide. The preparation was dried, fixed by heat and stained with crystal violet. The number of yeasts per BEC 50 was quantified by optical microscopy. Folded or overlapping cells were excluded. After counting, the mean and standard deviation of each strain weretaken.

Antifungal susceptibility testing

Susceptibility to fluconazole, izoconazole, voriconazole, ketoconazole and amphotericin B were performed according to the M27-A3 document of the CLSI [30]. Fluconazole (Pfizer, São Paulo, Brazil), isoconazole, voriconazole, ketoconazole (Jansen Pharmaceutica, Beerse, Belgium) and amphotericin B (Sigma, St Louis, Millstone, USA) were obtained as reagent grade powders. Stock solutions were prepared in dimethylsulfoxide (amphotericin B) or water (fluconazole, isoconazole, voriconazole and ketoconazole). Serial two-fold dilutions were prepared, and dilutions were made in RPMI 1640 medium (Sigma) buffered to pH 7 with 0.165 M morpholinopropanesulfonicacid (Sigma). Aliquots (100 μL) of each agent at a two-fold final concentration were dispensed into the wells of plastic microdilution trays. The trays containing fluconazole, isoconazole, voriconazole and ketoconazole were sealed and frozen at -70 °C until used. Amphotericin B was prepared immediately before use.

The inoculum suspension was adjustedwith a spectrophotometer (660 nm) to a final density of 1.5 ± 1.0 x103 cells/ml. Final concentrations of the antifungal agents ranged between 0.03 and 64 μg/ml. The trays were incubated at 35 °C and the MIC (Minimum Inhibitory Concentration) endpoints were read after 48 h of incubation. Drug-free and yeast control wells were included.

Following incubation, the MICs of fluconazole, isoconazole, voriconazole and ketoconazole were read as the lowest concentration at which a prominent decrease (approximately 80 %) in turbidity was observed compared to the drug-free control. The MICs of amphotericin B were read as inhibition of 100 % of the growth. The interpretative criteria for the susceptibility to fluconazole, isoconazole, voriconazole and ketoconazole were used as described elsewhere [15, 30]. No interpretative criteria were defined for amphotericin B; however, for comparison, isolates inhibited by concentrations <1.0 μg/ml were considered susceptible.

CBA analysis of cytokines

The determination of cytokines in the serum from 33 cancer patients (randomly selected) and 31 from control individuals was determined using the human Th1/Th2 cytokine cytometric bead array (CBA) kit (BD PharMingen, San Diego, CA). Cytokines IL-2, IL-4, IL-6, IL-10, IL-17, TNF-α and IFN-γ were detected simultaneously by adding 50 μL of each sample mixed with 50 μL of mixed capture beads and 50 μL of the human Th1/Th2 PE detection reagent consisting of PE-conjugated anti-human cytokines. The samples were incubated at room temperature for 3 h in darkness. After incubation with the PE detection reagent, samples were washed once and resuspended in 300 μL of wash buffer before acquisition on the FACSCalibur (BD Biosciences, Sunnyvale, CA). Data were analyzed using CBA software (BD PharMingen). Standard curves were generated for each cytokine using the mixed cytokine standard provided by the kit. The concentration for each cytokine in cell supernatants was determined by interpolation from the corresponding standard curve. The range of detection was 20–5000 pg/mL for each cytokine measured by CBA.

Statistical analysis

Analysis of variance (ANOVA) was performed using the process of Minimum Significant Difference (MSD) for comparison of means. Student t testwas used to compare means, where pvalues ≤ 0.05 were considered statistically significant. Calculations were performed using EPISTAT (TL Gustafson, Round Rock, USA) software.

Results

Study group

Approximately 50 (85 %) cancer patients were positive for culture of Candida species in the oral mucosa. In the control group, 20 patients showed strains of Candida in theoral cavity (59 %). Of the 50 individuals in the study group (orogastric cancer), there were21 (42 %) with oral cancers, 14 (28 %) with esophageal cancer, 2 (4 %) with neck cancer, 7 (14 %) with stomach cancer, and 6 (12 %) with laryngeal cancer.

A total of 83 Candida isolates representing 6 different species were isolated from patients with orogastric cancer and individuals without cancer (control group). All patients in this study (control and test groups) had no clinical signs and no symptoms of candidiasis. However, they were colonized by yeasts of the gender Candida.

All isolates were identified by MALDI-TOF MS. In the group of cancer patients, 32 (51.6 %) isolates were identified as Candida albicans, 4 (6.5 %) as C. tropicalis, 9 (14.5 %) as C. glabrata, 4 (6.5 %) as C. krusei, 8 (12.9 %) as C. parapsilosis and 5 (8 %) as C. lusitaniae. The control group included 14 (66.7 %) isolates identified as C. albicans, 5 (23.8 %) as C. parapsilosis, 1 (4.8 %) as C. krusei and 1 (4.8 %) as C. glabrata. Some patients have more than one species of Candida in the oral cavity, while not presenting clinical manifestation of candidiasis. Patients with more than one yeast are YCa 36, 37 e 38 – C. albicans, C. parapsilosis and C. glabrata and YCa 48, 49 and 50 – C. albicans, C. parapsilosis and C. lusitaniae. YCa 22 and 23 – C. albicans and C. krusei, YCa 40 and 41 – C. glabrata and C. lusitaniae, YCa 42 and 43 – C. glabrata and C. lusitaniae, YCa 44 and 45 – C. parapsilosis and C. albicans, Yca 46 and 47 – C. albicans and C. glabrata, YCa 54 and 55 – C. albicans and C. parapsilosis, YCa 56 and 57 – C. lusitaniae and C. glabrata, YCa 58 and 59 – C. albicans and C. lusitaniae.

Adhesion, phospholipases and proteinases

The Candida strains isolated from the oral cavity of subjects with cancer were more adherent than those of the oral cavity of people without alteration of the mucosa (p ≤ 0.05). The group with cancer had the double of the number of adhered yeast cell compared to the control group. The median number of yeast to 430 CEB was 2 in yeast strains from patients with cancer. In Candida strains isolated from individuals with normal oral mucosa (control group), this value was 1. Minimum values were zero for both groups and the maximum values were 21 and 18 for the cancer and control groups, respectively. The statistical analysis for nonparametric data showed differences between the two groups (p ≤ 0.05).

The PZ value was determined as the ratio of the diameter of the colony to the total diameter of the colony plus the precipitation zone, and it was scored and categorized as follows: PZ value = 1 (negative); PZ value = 0.75-0.9 (low producers); PZ value = 0.51-0.74 (moderate producers); and PZ value = 0.35-0.5 (high producers) [31]. For phospholipases production, 54.2 % of yeast strains produced the enzyme on solid medium. In addition, 32.5 % of the yeast strains produced proteinase. Only 13.3 % of the isolates were positive for the production of phospholipases and proteinases (Table 1).
Table 1

Proteinases and phospholipases activity of Candida spp. isolates from patients with orogastric cancer and healthy individuals (control group)

Isolates

Phospholipase

Proteinase

YCa1

C. albicans

N

N

YCa2

C. parapsilosis

N

N

YCa3

C. parapsilosis

HP

N

YCa4

C. glabrata

HP

HP

YCa5

C. albicans

N

N

YCa6

C. albicans

HP

N

YCa7

C. albicans

HP

N

YCa8

C. albicans

HP

N

YCa9

C. albicans

HP

HP

YCa10

C. albicans

N

N

YCa11

C. albicans

N

N

YCa12

C. albicans

N

N

YCa13

C. albicans

HP

N

YCa14

C. albicans

HP

PO

YCa15

C. tropicalis

HP

HP

YCa16

C. albicans

N

HP

YCa17

C. glabrata

HP

HP

YCa18

C.albicans

PO

N

YCa19

C. glabrata

N

P

YCa20

C. albicans

HP

N

YCa21

C. glabrata

N

PO

YCa22

C. albicans

N

N

YCa23

C. krusei

HP

HP

YCa24

C. albicans

N

N

YCa25

C. tropicalis

HP

PO

YCa26

C. krusei

N

N

YCa27

C. glabrata

N

HP

YCa28

C. parapsilosis

HP

HP

YCa29

C. tropicalis

N

N

YCa30

C. albicans

HP

N

YCa31

C. albicans

HP

HP

YCa32

C. parapsilosis

HP

HP

YCa33

C. albicans

HP

N

YCa34

C. albicans

HP

N

YCa35

C. tropicalis

N

N

YCa36

C. albicans

HP

N

YCa37

C. parapsilosis

N

N

YCa38

C. glabrata

N

HP

YCa39

C. krusei

N

HP

YCa40

C. glabrata

N

HP

YCa41

C. lusitaniae

N

HP

YCa42

C. albicans

HP

N

YCa43

C. lusitaniae

N

PO

YCa44

C. albicans

HP

N

YCa45

C. parapsilosis

N

HP

YCa46

C. albicans

HP

N

YCa47

C. glabrata

N

HP

YCa48

C. albicans

HP

N

YCa49

C. parapsilosis

N

HP

YCa50

C. lusitaniae

N

N

YCa51

C. krusei

N

HP

YCa52

C. albicans

HP

N

YCa53

C. albicans

HP

N

YCa54

C. albicans

HP

N

YCa55

C. parapsilosis

HP

HP

YCa56

C. lusitaneae

N

HP

YCa57

C. glabrata

N

HP

YCa58

C. albicans

N

N

YCa59

C. lusitaniae

N

N

YCa60

C. albicans

HP

N

YCa61

C. albicans

HP

N

YCa62

C. albicans

HP

N

YCo2

C. albicans

HP

N

YCo3

C. parapsilosis

N

N

YCo4

C. parapsilosis

N

N

YCo5

C. albicans

HP

N

YCo7

C. albicans

HP

N

YCo11

C. albicans

HP

N

YCo13

C. albicans

N

N

YCo16

C. glabrata

N

N

YCo17

C. parapsilosis

N

N

YCo9

C. albicans

HP

N

YCo23

C. para

N

N

YCo26

C. albicans

HP

N

YCo28

C. albicans

HP

N

YCo33

C. para

N

N

YCo35

C. albicans

HP

N

YCo36

C. albicans

HP

N

YCo37

C. albicans

HP

N

YCo39

C. albicans

HP

HP

YCo42a

C. albicans

HP

N

YCo42b

C. krusei

N

N

YCo43

C. albicans

HP

N

YCa yeasts from patientes with cancer, YCo yeasts from control group, HP high positive, PO Positive

Susceptibility assays

A total of 83 isolates of Candida spp. were analyzed for their susceptibility to ketoconazole (KET), fluconazole (FLU), isoconazole (ISO), amphotericin B (AmpB), and voriconazole (VOR). The results of these assays are presented in Table 2. MIC values were determined after 24 h of incubation, as most yeast had a strong increase in the MIC from 24 to 48 h, with a high growth, called trailing. Interpretive criteria for susceptibility to fluconazole and isoconazole were adopted as published by Rex et al. [32], and Fothergill et al. [33]. We considered strains susceptible when MIC was < 8.0 μg/mL for these drugs. For voriconazole, interpretive criteria for susceptibility of the CLSI (2008) were adopted. We considered yeast strains susceptible when the MIC was < 1.0 μg/mL. Interpretation criteria for amphotericin B were determined following the standards adopted by the CLSI [19]: yeast strains were considered susceptible when the MIC was < 1.0 μg/mL. The results are presented in Table 2.
Table 2

Susceptibility profile of Candida spp. isolates from patients with orogastric cancer and healthy individuals (control group)

Antifungal drugs

Species

Cancer orogastric patients

Control group

  

MIC90 24 h

Range MIC 24 h

MIC 90 48 h

Range MIC 48

MIC90 24 h

Range MIC 24 h

MIC 90 48 h

Range MIC 48

  

Concentration (μg/mL)

Concentration (μg/mL)

 

C. albicans

32d

0.125–32

64d

1.0 – 64

32a

0,25–32

64d

0.5–64

FLU

C. glabrata

8.0d

0.5– 32

32d

8.0 – 64

0.25a

0.25

2.0a

2.0

 

C. parapsilosis

8.0a

0.5–16

16d

8.0–64

1.0a

0.5–4.0

8.0a

0.5–32

 

C .krusei

4.0a

0.5–32

0.5a

0.25–64

0.25a

0.25

0.25a

0.25

 

C. tropicalis

64d

1.0–64

64d

32–64

-

-

-

-

 

C. lusitaniea

8.0a

4.0–8.0

64d

64

-

-

-

-

 

C. albicans

8.0a

0.0625–32

16d

0.25–64

4.0a

0.125 –32

32d

0.25–64

 

C. glabrata

0,5a

0.25–4

4.0a

1.0– 32

0

0

2.0a

2.0

ISO

C. parapsilosis

1.0a

0.0625–1.0

2.0a

0.5–8

2.0a

0.5–2.0

.0a

1.0–32

 

C. krusei

0

0–32

4.0a

0–32

0

0

0

0

 

C. tropicalis

4.0a

0.125–16

8.0a

2.0–32

-

-

-

-

 

C. lusitaniea

0

0–2.0

8.0a

1.0–16

-

-

-

-

 

C. albicans

64d

0.0625–64

64d

0.0625–64

2.0d

0.125–2.0

64d

0.25–64

 

C. glabrata

2.0d

0.25–2.0

4.0d

4.0 – 64

0

0

0.25a

0.25

VOR

C. parapsilosis

2.0d

0.25–2

4.0d

1.0–64

0.125a

0–0.5

2.0d

0.25–64

 

C. krusei

0

0–8.0

2.0d

0–16

0

0

0

0

 

C. tropicalis

32d

0.5–64

64d

32–64

-

-

-

-

 

C. lusitaniea

1.0a

0–16

16d

1.0–64

-

-

-

-

 

C. albicans

0.5a

0.125–32

0.5a

0.125–32

0.5a

0.25–0.5

0.5a

0.25–0,5

 

C. glabrata

0.5a

0.25– 0.5

0.5a

0.25–1.0

0

0

0.25a

0.25

Amp. B

C. parapsilosis

0,5a

0.0625–0.5

0.5a

0.0625–0.5

0.25a

0.25–0.5

0.5a

0.25–0.5

 

C. krusei

0.5a

0–32

0.25a

0.25–32

0.5a

0.5

0.5a

0.5

 

C. tropicalis

0.5a

0.25–0.5

0.5a

0.25–1.0

-

-

-

-

 

C. lusitaniea

0.5a

0.5

0.5a

0.5

-

-

-

-

 

C. albicans

32d

0.0625–32

32d

0.125–64

0.125a

0–0.125

64d

0.25–64

 

C. glabrata

0.5a

0.125–1.0

2.0a

0.25–64

0

0

0.25a

0.25

KET

C. parapsilosis

0.5a

0.125–0.5

1.0a

0.5–32

0.125a

0–0.5

1.0a

0.25–4

 

C. krusei

0

0–32

0

0–32

0

0

0

0

 

C. tropicalis

4.0d

0–16

2.0d

2.0–64

-

-

-

-

 

C. lusitaniea

0.5a

0–1.0

4.0d

0–32

-

-

-

-

asusceptible, bsusceptible dose-dependent, cintermediate resistance, dresistance; MIC90 Inhibition = 90 % of isolates

A variation between the maximum and minimum values of MIC for each species for both individuals test group as in the control group was observed. The MIC90 values represent the concentration of the antifungal drug that inhibited the growth of 90 % of isolates. The data were computed as the concentrations of antifungal agent necessary to inhibit 90 % of the isolates (MIC90) of the yeasts. C. albicans strains from both cancer patients and from the control group taken together gave an MIC90 value for amphotericin B, fluconazole and voriconazole of 64 μg/mL. For isoconazole, the MIC90 values for the yeast strains isolated from orogastric cancer patients and fromthe control group were 16 μg/mL and 32 μg/mL, respectively. In addition, The MIC90 value for C. albicans with ketoconazole was 1 μg/mL for the two evaluated groups. For non-albicans yeast isolated from patients with orogastric cancer, the MIC90 values for amphotericin B ranged from 1-64 μg/mL, for fluconazole it was 64 μg/mL, for isoconazole it ranged from 16-64 μg/mL, for ketoconazole it was 0.5 μg/mL and for voriconazole it ranged from 1.8-64 μg/mL. In addition, for non-albicans strains isolated from healthy individuals, the MIC90 value for amphotericin B and fluconazole was64 μg/mL. Moreover, the MIC90 values for voriconazole, isoconazole and ketoconazole were ≥ 0.5, ≥4 and 1 μg/mL, respectively.

Serum cytokine detection

Serum cytokine levels in patients with orogastric cancer and control group are shown in Table 3 and Fig. 1. According to the results, a statistically significant increase of IL-2, IL-10, TNF-α, IFN-γ, and IL-17 was observed in patients with cancer compared with the control group. IFN-γ was detected in 57.6 % of study cases and in 6.45 % of the control cases. The mean value of serum IFN-γ levels in patients from the study group (patients with orogastric cancer) was 18.2 ± 32.28 ρg/mL. In the control group, the mean IFN-γ value was 0.77 ± 3.92 ρg/mL. The mean value of serum IFN-γ levels in the study group was significantly different from that in the control group (p = 0.0001).
Table 3

Serum levels of cytokines (ρg/mL) in the investigated individuals

 

Patients with cancer

Control group

N

Detectability

Min

Max

Mean ± SD

N

Detectability

Min

Max

Mean ± SD

IFN-γ

19

57.6 %

0

149.39

18.2 ± 32.28

2

6.45 %

0

21,81

0.77 ± 3.92

TNF-α

20

60.6 %

0

93.69

9.71 ± 19.06

5

15.15 %

0

1.55

0.22 ± 0.53

IL-2

26

78.8 %

0

93.03

10,71 ± 19.31

17

54.8 %

0

10.66

1.48 ± 2.08

IL-4

13

39.4 %

0

128.81

11.04 ± 26.23

28

90.3 %

0

11.57

2.42 ± 1.94

IL-6

16

48.5 %

0

219.16

16.97 ± 43.99

31

100 %

0

10,29

3.78 ± 1.79

IL-10

27

81.8 %

0

91.44

8.66 ± 15.84

30

96.8 %

0

11.43

2.36 ± 1.99

IL-17

23

69.7 %

0

356.21

33.36 ± 68.29

5

16.12 %

0

1.55

0.60 ± 3.37

N number of individual

Fig. 1

Panel measured cytokines in the serum of control subjects (CT = 31) and patients with cancer (CA = 33). Average between the existing values. IL-2 p = 0.0001, IL-10 p = 0.0007, p = 0.0001 TNF-α, IFN-γ p = 0,0001 e IL-17 p = 0,0002

TNFα was detected in 60.6 % of the patients and in 16 % of the individuals from the control group. The mean value of serum TNFα levels in patients from the study group (patients with orogastric cancer) was 9.71 ± 19.06 pg/mL. In the control group, the mean TNFα value was 0.22 ± 0.53 ρg/mL. The mean value of serum TNFα levels in the study group was significantly different from that in the control group (p ≤ 0.0001).

Serum levels of IL-10 in patients from the control group was 81.8 % and 96.8 % in cancer subjects. The mean value of serum IL-10 level in the study group (patients with orogastric cancer) was 8.66 ± 15.84 pg/mL. In the control group, the mean value of IL-10 levels was 2.36 ± 1.99 ρg/mL. The mean value of serum IL-10 levels in study group was significantly different from that in the control group (p ≤ 0.001). Serum levels of IL-17 in individuals from the study weredetected in 69.7 % of patients in the study group and in 3.22 % of individuals in the control group. The mean value of serum IL-17 levels in patients in the study group (patients with orogastric cancer) was 33.36 ± 68.29 ρg/mL. In the control group, the mean value of IL-17 level was 0.6 ± 3.37 ρg/mL. The mean value of serum IL-17 levels in the study group was significantly different from that in the control group (p ≤ 0.0002).

Serum levels of IL-2 in individuals from this study were detected in 78 % of patients in the study group and in 54.8 % of the individualsinthe control group. The mean value of serum IL-2 levels in patients of the study group (patients with orogastric cancer) was 10.7 ± 19.31 ρg/mL. In the control group, the mean value of serum IL-2 levels was 1.48 ± 2.08 ρg/mL. The mean value of serum IL-2 levels in the study group was significantly different from that in the control group (p ≤ 0.0001).

Discussion

Infections by Candida species are common in cancer patients, and the incidence has increased in recent years [34, 35]. Several virulence factors contribute to Candida yeasts pathogenicity, being one of the main causers of fungemia in individuals with cancer and contributing to high mortality rates. In this study, it was observed that 85 % of individuals were colonized by one or more Candida species, with C. albicans being the most constant species followed by C. glabrata. These results are very similar to other previous reports. In a study conducted by Galle et al. [36] it was observed that among 31 % of patients with lesions of oral cancer, strains of C. albicans were the most prevalent species at 43.7 %, followed by C. glabrata and C. tropicalis.

A more adherent profile was detected for Candida species isolated from the oral cavity of individuals with cancer when compared to the strains isolated from the control group. Adhesion is considered an extremely important virulence factor in yeast given that the colonization and infection of oral tissues is directly related to adherence competence. This virulence factor may initially contribute to tissue invasion: once adhered to initiate the invasion, the yeast secretes enzymes that damage the mucosa. The higher phospholipase activity is related to stronger adherence to epithelial cells and increased pathogenicity [9]. Phospholipases and proteases activities and adhesion of microorganisms on cell surfaces are considered important virulence factors, facilitating the establishment of infection, especially in opportunistic fungi [37]. These enzymes facilitate adherence and tissue penetration and hence, host invasion. In this study, proteinases and phospholipases were detected in 6.4 % and 37.1 % of strains of C. albicans and 33.8 % and 14.5 %, respectively for non-albicans species. Phospholipases and proteases are produced at high rates by C. albicans, while species of Candida non-albicans generally have low levels of these enzymes [38]. Koga- Ito et al. [39] showed an increased production of proteinases and phospholipases between strains of C. albicans isolated from patients with oral candidiasis when compared with those isolated from control subjects.

Numerous studies regarding the MIC of Candida spp. isolates are found in the literature in recent years because of the increased incidence of invasive candidiasis, along with an increase in the isolation of species resistant to antifungal drugs [40]. Patients undergoing radiotherapy for head and neck cancer represent a serious challenge in relation to oral aftercare due to radiotherapy complications [41]. However, it is important to know the susceptibility of antifungal drugs before deciding on a specific treatment because some species are intrinsically resistant to certain antifungal drugs.

In this study, amphotericin B showed good activity against yeast strains from both cancer patients and from the control group, with MIC90 values of ≤1 μg ml/mL for all major isolates. In fact, all the isolates were susceptible, except for C. krusei. Only a few of Candida isolates (6.5 %) were resistant to isoconazole, and 8 % of Candida isolates showed resistance to voriconazole. However, 35 % of the yeasts from patients with cancer were resistant to fluconazole. This is of concern given that fluconazole has been used as a first line therapy for infections caused by Candida species other than C. glabrata and C. krusei [42].

In the present study, we observed that in patients who had orogastric cancer, inflammatory cytokines showed statistically significant increases compared to the control group (individuals considered healthy), showing agreement with the literature. Cancer development from the inflammatory process can be conducted by tumor-associated macrophages, as well as a variety of chemical mediators [43, 44]. More recently, inflammation has been shown to be a critical component in tumor progression [45]. Moreover, the emergence of several types of cancer can be observed at sites of infection and inflammation [45]. Immune cells and regulatory molecules secreted by these cells within the tumor microenvironment have key roles in antitumor immunity and evasion of the immune system [44, 46].

Previous studies in vitro with human cells and squamous cell carcinoma showed that the concentration of certain pro-inflammatory cytokines and pro-angiogenic cytokines, such as TNF-α, IL-1, IL-6 and IL-8, are increased. There is evidence that cytokines are produced in an unregulated way in oropharyngeal cancer and that they have roles in cellular invasion, interruption in suppressing tumor growth and immunological status [47, 48]. In this study, individuals with orogastric cancer also showed elevated levels of TNF-α, showing a close relationship with this type of tumor.

We observed that individuals with orogastric cancer also showed a high levels of IL-10 in their serum relative to the control group, showing agreement with other studies. It has been reported that IL-10 plays a role in carcinogenesis, which is considered controversial, in both promotion and inhibition of tumors [49]. In colorectal carcinogenesis, IL-10 promotes cancer growth, rather than inhibition, through its immunosuppressive activity [50, 51]. Previous studies have suggested that the increase in IL-10 can track inflammatory responses and cancer development and constitute a risk factor for carcinogenesis [51].

We also quantified Interleukin 17 (IL-17) in the serum of individuals with and without cancer and statistically significant differences were detected. Our data suggest that the immune status of these individuals was changed. Interleukin 17 (IL-17)-mediated immunity plays a key role in protection from fungal infections in mice and man [52, 53]. Here, we confirmed that mice deficient in IL-17 receptor or lacking the ability to secrete IL-17 are highly susceptible to systemic candidiasis [52]. Individuals with cancer investigated in the present study had no apparent candidiasis injury because collection was performed before the initiation of treatment, after confirmation of the diagnosis. However, given the existing changes in the immune system of these individuals, they were susceptible to opportunistic infections, such as candidiasis.

Gasparoto et al. [54] showed, in elder individuals, showed that the immunoregulatory cytokine IL-10 has the ability to inhibit IL-12 and IFN-γ, promoting an immune response type II and show that this type of response (Th2) is associated with the susceptibility of the host to infection by C. albicans [43]. According XIONG et al [55], the virulence of C. albicans may be related to its ability to selectively induce IL-10, with simultaneous inhibition of IL-12 and T cells IFN-γ allowing a greater susceptibility of the individual candidiasis [44]. Then, one can also conclude that early monitoring of levels of interleukins, in particular IL-10, may contribute tomaking clinical decisions regarding the prophylaxis forfungal infections subsequent or concomitant tothe treatment of malignant tumors.

Conclusion

It was possible to isolate Candida species in 85 % and 59 % of individuals with COG-C and in the control group, respectively. The species C. albicans was the most prevalent amidst the isolates. As for virulence factors, the isolates obtained from patients with cancer were more virulent than isolates from the control group. The results generated by MIC assessment showed that the isolates were susceptible to all antifungals compounds. The 20 drugs to which the yeast strains presented higher susceptibility were amphotericin B, ketoconazole and isoconazole. Regarding the cytokines evaluated in the serum of individuals with and without cancer, significant differences were observed among individuals with cancer for IL2, IL10, TNF-α, IFN-g and IL17.

Abbreviations

AmpB: 

amphotericin B

BEC: 

buccal epithelial cells

CBA: 

cytometric bead array

FLU: 

fluconazole

HBECs: 

human buccal cells

IFN-γ: 

interferon

IL-10: 

interleukin 10

IL-17: 

interleukin 17

IL-2: 

interleukin 2

ISO: 

isoconazole

KET: 

ketoconazole

MALDI-TOF: 

matrix assisted laser desorption ionization – time of flight

MG: 

Minas Gerais

MIC: 

minimum inhibitory concentration

MS: 

mass spectrometry

NaCl: 

sodium chloride

OGC: 

orogastric cancer

PZ: 

phospholipases

Sap: 

aspartyl proteinases

SDA: 

sabouraud dextrose agar

TNF-α: 

tumor necrosis factor

VOR: 

voriconazole.

YCa: 

yeasts cancer

YCo: 

yeasts control

Declarations

Acknowledgements

The field activity of this study was supported by theConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Fundação do Amparo a Pesquisa do Estado do Maranhão (FAPEMA).

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Laboratory of Mycology, Department of Microbiology, Institute of Biological Sciences, Federal University of Minas Gerais
(2)
Laboratory of Applied Microbiology, Department of Microbiology, Institute of Biological Sciences, Federal University of Minas Gerais
(3)
Laboratory of Microbiology, CEUMA University
(4)
Hospital of Federal University of Maranhão
(5)
Biomarkers Laboratory Diagnostics and Monitoring, Research Center René Rachou (CPqRR) - FIOCRUZ/MG
(6)
Laboratory of Microbiology, Vale do Rio Doce University
(7)
Laboratory of oral and anaerobic microbiology, Department of Microbiology, Institute of Biological Sciences, Federal University of Minas Gerais
(8)
Oncology Core Experts
(9)
Alvarenga Laboratory
(10)
Laboratory of Basic and Applied Virology, Department of Microbiology, Institute of Biological Sciences, Federal University Minas Gerais
(11)
Laboratory of General Bacteriology and Clinical, Department of Pathology, Federal University of Espirito Santo, Health Science Center

References

  1. World Health Organization. Cancer. Fact sheet N°297. February 2006. [homepage on the Internet]. Geneva: World Health Organization; c2007 [cited 2007 oct. 10]. Available from: http://www.who.int/en/. Accessed February 2015.
  2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–6.View ArticlePubMedGoogle Scholar
  3. Basson NJ. Competition for glucose between Candida albicans and oral bacteria grown in mixed culture in a chemostat. J Med Microbiol. 2000;49:969–75.View ArticlePubMedGoogle Scholar
  4. Kanaguchi N, Narisawa N, Ito T, Kinoshita Y, Kusumoto Y, Shinozuka O, et al. Effects of salivary protein flow and indigenous microorganisms on initial colonization of Candida albicans in an in vivo model. BMC Oral Health. 2012;12:36.PubMed CentralView ArticlePubMedGoogle Scholar
  5. Boriollo MF1, Spolidorio DM, Barros LM, Bassi RC, Garcia JA, Costa AM, et al. Typing Candida albicans oral isolates from healthy brazilian schoolchildren using multilocus enzyme electrophoresis reveals two highly polymorphic taxa. Braz J Microbiol. 2011;42:1030–46.PubMed CentralView ArticlePubMedGoogle Scholar
  6. Alnuaimi AD, Wiesenfeld D, O'Brien-Simpson NM, Reynolds EC, McCullough MJ. Oral Candida colonization in oral cancer patients and its relationship with traditional risk factors of oral cancer: a matched case-control study. Oral Oncol. 2015;51:139–45.View ArticlePubMedGoogle Scholar
  7. Slavin MA, Sorrell TC, Marriott D, Thursky KA, Nguyen Q, Ellis DH, et al. Candidemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother. 2010;65:1042–51.View ArticlePubMedGoogle Scholar
  8. Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001–2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer. 2009;115:4745–52.View ArticlePubMedGoogle Scholar
  9. Mohan das V, Ballal M. Proteinase and phospholipase activity as virulence factors in Candida species isolated from blood. Rev Iberoam Micol. 2008;25:208–10.View ArticlePubMedGoogle Scholar
  10. Naglik JR, Moyes D, Makwana J, Kanzaria P, Tsichlaki E, Weindl G, et al. Quantitative expression of the Candida albicans secreted aspartyl proteinase gene family in human oral and vaginal candidiasis. Microbiology. 2008;154:3266–80.PubMed CentralView ArticlePubMedGoogle Scholar
  11. Olsen I. Oral adhesion of yeasts. Acta Odontol Scand. 1990;48:45–53.View ArticlePubMedGoogle Scholar
  12. Ashman RB. Protective and pathologic immune responses against Candida albicans infection. Front Biosci. 2004;13:3334–51.Google Scholar
  13. Gligorov J, Bastit L, Gervais H, et al. Prevalence and treatment management of oropharyngeal candidiasis in cancer patients: results of the French Candidoscope study. Int J Radiat Oncol Biol Phys. 2011;80:532–39.View ArticlePubMedGoogle Scholar
  14. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38:I6I–89.View ArticleGoogle Scholar
  15. Espinel-Ingroff A. Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005–2009). Rev Iberoam Micol. 2009;26:15–22.View ArticlePubMedGoogle Scholar
  16. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6:24–37.View ArticlePubMedGoogle Scholar
  17. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007;117:1175–83.PubMed CentralView ArticlePubMedGoogle Scholar
  18. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006;90:1–50.View ArticlePubMedGoogle Scholar
  19. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14:218–28.View ArticleGoogle Scholar
  20. Blanco JL, Garcia ME. Immune response to fungal infections. Vet Immunol Immunopathol. 2008;125:47–70.View ArticlePubMedGoogle Scholar
  21. der Walt V, Yarrow D. Methods for isolation, maintenance, classification and identification of yeasts, p 45-104. In: Kreger van-Rij NJW, editor. The yeasts: a taxonomic study. 3rd ed. Amsterdam: Elsevier Science Publishers; 1984. p. 1082.Google Scholar
  22. Kurtzman CP, Fell JD. The yeast, a taxonomic study, 4th edition, Elsevier; 1998.Google Scholar
  23. Pinjon E, Sullivan D, Salkin I, Shanley D, Coleman D. Simple, inexpensive, reliable method for differentiation of Candida dubliniensis from Candida albicans. J Clin Microbiol. 1998;36:2093–95.PubMed CentralPubMedGoogle Scholar
  24. Chowdhary A, Randhawa HS, Kowshik T, Kathuria S, Roy P, Brandt ME. Application of hypertonic Sabouraud glucose agar for differentiation of Candida dubliniensis from Candida albicans. Diagn Microbiol Infect Dis. 2011;69:440–42.View ArticlePubMedGoogle Scholar
  25. Cassone A, De Bernardis F, Mondello F, Ceddia T, Agatensi L. Evidence for a correlation between proteinase secretion and vulvovaginal candidosis. J Infect Dis. 1987;156:777–83.View ArticlePubMedGoogle Scholar
  26. DeBernardis F, Mondello F, San Millan R, Pontòn J, Cassone A. Biotyping and virulence properties of skin isolates of Candida parapsilosis. J Clin Microbiol. 1999;3281–86.Google Scholar
  27. Kantarcioglu AS, Yucel A. Phospholipase and protease activities in clinical Candida isolates with reference to the sources of strains. Mycoses. 2002;45:160–65.View ArticlePubMedGoogle Scholar
  28. Machado AG, Komiyama EY, Santos SSF, Jorge AOC, Brighentif L, Koga-Ito CY. In vitro adherence of Candida albicans isolated from patients with chronic periodontitis. J Appl Oral Sci. 2011;19:384–87.PubMed CentralView ArticlePubMedGoogle Scholar
  29. Kimura LH, Pearsall NN. Adherence of Candida albicans to human buccal epithelial cells. Infect Immun. 1978;21:64–8.PubMed CentralPubMedGoogle Scholar
  30. Clinical and Laboratory Standards Institute (CLSI). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 3ªth ed. Pennsylvania: USA: CLSI document M27-A3; 2008.Google Scholar
  31. Mattei AS, Alves SH, Severo CB, Guazzelli LS, Oliveira FM, Severo LC. Determination of germ tube, phospholipase, and proteinase production by bloodstream isolates of Candida albicans. Rev Soc Bras Med Trop. 2013;46:340–42.View ArticlePubMedGoogle Scholar
  32. Rex JH, Pfaller MA, Walsh TJ, ChaturvedI V, EspineL-Ingroff A, Ghannoum MA, et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microbiol Rev. 2001;14:643–58.PubMed CentralView ArticlePubMedGoogle Scholar
  33. Fothergill AW. Antifungal Susceptibility Testing: Clinical Laboratory and Standards Institute (CLSI) Methods. Chapter 2. 2012. p. 65–72.Google Scholar
  34. Kofteridis DP, Lewis RE, Kontoyiannis DP. Caspofungin-non-susceptible Candida isolates in cancer patients. J Antimicrob Chemother. 2010;65:293–95.View ArticlePubMedGoogle Scholar
  35. Mokaddas E, Khan ZU, Ahmad S. Prevalence of Candida dubliniensis among cancer patients in Kuwait: a 5-year retrospective study. Mycoses. 2011;54:29–34.View ArticleGoogle Scholar
  36. Galle F, Colella G, Di Onofrio V, Rossiello R, Angelillo IF, Liguori G. Candida spp. in oral cancer and oral precancerous lesions. New Microbiol. 2013;36:283–88.Google Scholar
  37. Yang YL. Virulence factors of Candida species. J Microbiol Immunol Infect. 2003;36:223–28.PubMedGoogle Scholar
  38. Gokce G, Cerikcioglu N, Yagci A. Acid proteinase, phospholipase, and biofilm production of Candida species isolated from blood cultures. Mycopathologia. 2007;164:265–69.View ArticlePubMedGoogle Scholar
  39. Koga-Ito CY, Lyon JP, Vidotto V, Resende MA. Virulence factors and antifungal susceptibility of Candida albicans isolates from oral candidosis patients and control individuals. Mycopathologia. 2006;161:219–23.View ArticlePubMedGoogle Scholar
  40. Saghrouni F, Bougmiza I, Ben Abdeljelil J, Yacoub A, Khammari I, Fathallah A, et al. Epidemiological trends in invasive candidiasis: results from a 15 year study in Sousse region Tunisia. J Mycol Med. 2011;21:123.View ArticleGoogle Scholar
  41. Lalla RV, Brennan MT, Schubert MM. Oral complications of cancer therapy. In: Yagiela JA, Dowd FJ, Johnson BS, Mariotti A, Neidle EA, editors. Pharmacology and therapeutics for dentistry. 6th ed. St. Louis: Mo: Mosby Elsevier; 2011. p. 782–98.Google Scholar
  42. Amran F, Aziz MN, Ibrahim HM, Atiqah NH, Parameswari S, Hafiza MR, et al. In vitro antifungal susceptibilities of Candida isolates from patients with invasive candidiasis in Kuala Lumpur Hospital, Malaysia. J Med Microbiol. 2011;60:1312–16.View ArticlePubMedGoogle Scholar
  43. Eiró N, Vizoso FJ. Inflammation and cancer. World J Gastrointest Surg. 2012;4:62–72.PubMed CentralView ArticlePubMedGoogle Scholar
  44. Lu W, Lu L, Feng Y, Chen J, Li Y, Kong X, et al. Inflammation promotes oral squamous carcinoma immune evasion via induced programmed death ligand 1 surface expression. Oncol Lett. 2013;5:1519–26.PubMed CentralPubMedGoogle Scholar
  45. Landskron, Glauben Marjorie De la Fuente, Peti Thuwajit, Chanitra Thuwajit, Marcela A. Hermoso chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014 Article ID 149185:19. http://dx.doi.org/10.1155/2014/149185.
  46. Moore MM, Chua W, Charles KA. ClarkeSJ: Inflammation and cancer: causes and consequences. Clin Pharmacol Ther. 2010;87:504–8.View ArticlePubMedGoogle Scholar
  47. Rhodus NL, Ho V, Miller CS, Myers S, Ondrey F. NF-κB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detec Prev. 2005;29:42–5.View ArticlePubMedGoogle Scholar
  48. Rhodus NL, Cheng B, Myers S, Miller L, Ondery F. The feasibility of monitoring NF-κB associated cytokines: TNF-α, IL-1α, IL-6, and IL-8 in whole saliva for the malignant transformation of oral lichen planus. Mol Carcinog. 2005;44:77–82.View ArticlePubMedGoogle Scholar
  49. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol. 2005;78:1043–51.View ArticlePubMedGoogle Scholar
  50. Stanilov N, Miteva L, Deliysky T, Jovchev J, Stanilova S. Advanced colorectal cancer is associated with enhanced IL-23 and IL-10 serum levels. Lab Med. 2010;41:159–63.View ArticleGoogle Scholar
  51. Wang Y, Liu XH, Li YH, Li O. The paradox of IL-10mediated modulation in cervical cancer. Biomed Rep. 2013;1:347–51.PubMed CentralPubMedGoogle Scholar
  52. Bär E, Whitney PG, Moor K, Sousa CR, Gut-Landmann SL. IL-17 Regulates systemic fungal immunity by controlling the functional competence of NK cells. Immunity. 2014;40:117–27.View ArticlePubMedGoogle Scholar
  53. Saijo S, Ikeda S, Yamabe K, Kakuta S, Ishigame H, Fujikado N, et al. Dectin-2 recognition of alpha-mannans and induction of Th17 cell differentiation is essential for host defense against Candida albicans. Immunity. 2010;32:681–91.View ArticlePubMedGoogle Scholar
  54. Gasparoto TH, De Oliveira CE, Vieira NA, Porto VC, Gasparoto CT, Campanelli AP, et al. The pattern recognition receptors expressed on neutrophils and the associated cytokine profile from different aged patients with Candida-related denture stomatitis. Exp Gerontol. 2012;47:741–48.View ArticlePubMedGoogle Scholar
  55. Xiong J, Kang K, Liu L, Yoshida Y, Cooper KD, Ghannoum MA. Candida albicans and Candida krusei differentially induce human blood mononuclear cell interleukin-12 and gamma interferon production. Infect Immun. 2000;68:2464–69.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© de Sousa et al. 2016

Advertisement